For individuals living with Transthyretin Amyloid Cardiomyopathy (ATTR-CM), a debilitating condition, the arrival of Tafamidis and Tafamidis meglumine represents a genuine change. These novel therapies stabilize the transthyretin protein, halting its destructive build-up and alleviating the severity of the disease . Patients are now reporting po… Read More